Who is the manufacturer of humira

Although the initial US Humira patent expired in December , AbbVie is using its patent portfolio and newer patents for the drug's manufacturing methods and formulations to gain extra years of exclusivity. This did cost AbbVie significant revenue, but it also gave AbbVie a specific date to work with as they forecast their own future.

When approached for this article, the company declined to comment. AbbVie has also received criticism for steep price increases and it is not uncommon for drug companies to increase prices of drugs bi-annually. Phase III clinical trials are extremely expensive though so in many respects with the evolution of the lifecycle and added indications, there is some justification for the price increases for Humira.

AbbVie will focus on developing a stronger pipeline in more areas to manage the expected biosimilar erosion Humira will eventually experience. Now though, as delays are keeping Humira prices very high, there is concern. From a patient perspective, compliance will be an issue. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers.

Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. Tell your doctor about all of your health conditions , including if you: Have an infection, are being treated for infection, or have symptoms of an infection Get a lot of infections or infections that keep coming back Have diabetes Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB Live or have lived in an area such as the Ohio and Mississippi River valleys where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis.

These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle. Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.

Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth. Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.

Blood problems decreased blood cells that help fight infections or stop bleeding. Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.

Heart failure new or worsening. Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain. Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.

Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach abdomen. These problems can lead to liver failure and death. Psoriasis new or worsening. Symptoms include red scaly patches or raised bumps that are filled with pus. Remember, tell your doctor right away if you have an infection or symptoms of an infection, including: Fever, sweats, or chills Muscle aches Cough Shortness of breath Blood in phlegm Weight loss Warm, red, or painful skin or sores on your body Diarrhea or stomach pain Burning when you urinate Urinating more often than normal Feeling very tired HUMIRA is given by injection under the skin.

Humira moved to AbbVie, where it remains today. Humira: building a blockbuster Chronic life-long diseases requiring ongoing therapies and conditions with large populations lend themselves to large revenue streams for drugs such as Humira.

In AbbVie launched the Humira Pen, a self-injecting device, and it is currently in Phase III clinical trials for three additional indications — unspecified arthritis, peripheral spondyloarthritis and pyoderma gangrenosum. Employing an efficient marketing strategy for Humira has also been of benefit to AbbVie. This did cost AbbVie significant revenue, but it also gave AbbVie a specific date to work with as they forecast their own future.

When approached for this article, the company declined to comment. Phase III clinical trials are extremely expensive though so in many respects with the evolution of the lifecycle and added indications, there is some justification for the price increases for Humira.